| 000 | 01335 a2200337 4500 | ||
|---|---|---|---|
| 005 | 20250515205549.0 | ||
| 264 | 0 | _c20100615 | |
| 008 | 201006s 0 0 eng d | ||
| 022 | _a1531-6963 | ||
| 024 | 7 |
_a10.1097/BOR.0b013e3283373fa0 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGeyer, Matthias | |
| 245 | 0 | 0 |
_aActual status of antiinterleukin-1 therapies in rheumatic diseases. _h[electronic resource] |
| 260 |
_bCurrent opinion in rheumatology _cMay 2010 |
||
| 300 |
_a246-51 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xpharmacology |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAntirheumatic Agents _xtherapeutic use |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aImmunologic Factors _xtherapeutic use |
| 650 | 0 | 4 |
_aInterleukin 1 Receptor Antagonist Protein _xpharmacology |
| 650 | 0 | 4 |
_aInterleukin-1 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aReceptors, Interleukin-1 _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aRecombinant Fusion Proteins _xpharmacology |
| 650 | 0 | 4 |
_aRheumatic Diseases _xdrug therapy |
| 700 | 1 | _aMüller-Ladner, Ulf | |
| 773 | 0 |
_tCurrent opinion in rheumatology _gvol. 22 _gno. 3 _gp. 246-51 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/BOR.0b013e3283373fa0 _zAvailable from publisher's website |
| 999 |
_c19521314 _d19521314 |
||